+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 5 Actively Recruiting clinical trials

O

Actively Recruiting

Researchers are evaluating patient characteristics, treatment patterns, and both short- and long-term outcomes in people with symptomatic obstructive hypertrophic cardiomyopathy HCM in the United States and Europe. The study focuses on patients receiving mavacamten, other treatments, or no treatment due to intolerance or previous treatment failure. The US sub-study particularly assesses mavacamtens safety, while the European sub-study evaluates both the safety and effectiveness of mavacamten in real-world settings. Participants receive treatment as prescribed by their physicians according to standard care for symptomatic obstructive HCM. One group takes mavacamten, while another receives beta-blockers, non-dihydropyridine calcium channel blockers, andor disopyramide. Some participants may be untreated due to intolerance or treatment failure. Treatments follow routine clinical care without study-driven changes. Throughout the study, participants are monitored for heart function changes, including heart failure events and left ventricular outflow tract gradients, over periods up to five years. Researchers collect data on arrhythmias, hospitalizations, mortality, and quality of life using questionnaires and biomarker tests. This observational registry captures real-world experiences to better understand treatment outcomes and patient health over time.

Age: 18Years +All Genders
101 locations
O

Actively Recruiting

This observational study aims to collect clinical information on the safety and performance of the NEXUS Aortic Arch Stent Graft System and the Custom-Made NEXUS DUO Aortic Arch Stent Graft System for treating aortic aneurysms. The main questions focus on early mortality, safety outcomes, device failure, and procedural and hospitalization details. Participants are treated according to standard care at their institutions. Participants receive treatment per their institutions standard of care using either the NEXUS Aortic Arch Stent Graft System or the custom-made NEXUS DUO Aortic Arch Stent Graft System. The study includes both prospective and retrospective data collection with two groups based on the device used. Follow-up information is collected for up to five years after treatment. During the study, researchers will gather data on mortality at 30 days and 12 months, major adverse events, device failure, and other safety outcomes. Participants will undergo regular follow-up visits to monitor these outcomes and collect hospitalization and procedural information. The study is designed to observe real-world use of these devices and understand their longer-term safety and performance.

Age: 18Years +All Genders
18 locations
P

Actively Recruiting

Researchers are collecting data to evaluate the safety, performance, and clinical benefits of BIOTRONIKs electrophysiology EP products used in patients with cardiac arrhythmias. This observational, multi-center, international study aims to fulfill regulatory requirements and maintain approval of these devices in the CE region by monitoring any residual or newly emerging risks associated with their use. Participants in the study undergo routine diagnostic or therapeutic catheter interventions involving BIOTRONIK EP products, including catheters AlCath, MultiCath, ViaCath, external devices Qubic RF, Qubic Stim, Qiona, and transseptal sheaths Senovo Bi-Flex. These devices are applied temporarily during electrophysiology studies or catheter ablation procedures and used together with external equipment like RF generators, pacemakers, and irrigation pumps. During the study, participants data from these procedures and follow-ups will be collected to assess device deficiencies, adverse effects during and after procedures up to 3 to 6 months, and confirmations of clinical benefits at the time of procedure. Follow-up visits are required at the study sites to monitor safety and device performance over time, with the study expected to continue until July 2030.

Age: 18Years +All Genders
1 location
O

Actively Recruiting

Researchers are evaluating the real-world use of nemolizumab for treating moderate-to-severe atopic dermatitis AD in adolescents and adults. This observational study aims to assess the treatments effectiveness through physician evaluations and patient-reported outcomes over six months, providing insight into how the medication performs in everyday clinical practice. Participants receiving nemolizumab as part of their routine care will be observed for about 12 months. Treatment decisions are made by the participants physician before joining the study, with no extra visits or tests beyond usual medical care. A sub-study in Germany and the UK involves daily remote reporting of symptoms such as peak and average itch, sleep disturbance, and pain for the first two weeks. During the study, participants will have regular medical visits as determined by their doctors, with data collected from routine assessments and patient questionnaires. Researchers will measure outcomes like the Investigator Global Assessment and Peak Pruritus Numerical Rating Scale at six months, along with other severity and symptom scores up to 12 months. No additional procedures outside standard care are required, allowing for natural monitoring of treatment effects and safety.

Age: 12Years +All Genders
108 locations
E

Actively Recruiting

Researchers are conducting a Phase III international study to evaluate the effects of balcinrenone combined with dapagliflozin compared to dapagliflozin alone in patients with chronic heart failure HF and impaired kidney function who have recently experienced a heart failure event. The study aims to assess the impact of these treatments on cardiovascular death and heart failure events, including hospitalizations and other HF-related episodes. Participants are randomly assigned to one of three groups one receiving balcinrenonedapagliflozin 15 mg10 mg capsule plus placebo another receiving balcinrenonedapagliflozin 40 mg10 mg capsule plus placebo and a third group receiving dapagliflozin 10 mg tablet plus placebo capsule. All treatments are given once daily orally, alongside standard care for heart failure and kidney impairment. The study is conducted across approximately 700 sites in about 40 countries. During the trial, participants will be monitored over approximately 36 months for cardiovascular death, heart failure hospitalizations, and heart failure events without hospitalization. Assessments include heart failure symptom scores measured at 24 weeks post-randomization. Researchers will also track total occurrences of cardiovascular and heart failure events, as well as overall mortality. This long-term follow-up aims to evaluate treatment effects on these important health outcomes.

Age: 18Years - 130YearsAll GendersPhase 3
852 locations